Diagnostics News and Research

RSS

LabCorp announces collaboration between Esoterix Clinical Trials Services, Clearstone Central Laboratories

Laboratory Corporation of America Holdings announced today a collaboration between Esoterix Clinical Trials Services, a division of LabCorp, and Clearstone Central Laboratories, a global central laboratory specializing in drug development and pharmaceutical services.

13 Aug 2010

A*STAR's Singapore Immunology Network, Institut M-rieux and bioM-rieux partner in TB research

An investment of S$3 million is being pumped into tuberculosis (TB) research by A*STAR's Singapore Immunology Network (SIgN), bioindustrial group Institut M-rieux and its in vitro diagnostics company bioM-rieux. The project, which involves setting up a joint laboratory in Biopolis, Singapore aims to investigate and identify novel biomarkers that could allow early identification of individuals at risk of TB disease development and disease reactivation. This could lead to better diagnosis and treatment for the highly contagious disease.

13 Aug 2010

Transgenomic second-quarter net loss increases to $1.1 million

Transgenomic, Inc. today reported financial results for the three and six months ended June 30, 2010, and provided a business update.

13 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Entry deadline for second annual CLIO Healthcare Awards extended to August 27, 2010

The entry deadline has been extended for the second annual CLIO Healthcare Awards. All work appearing between January 1, 2009 and June 30, 2010 must be submitted to the CLIO Healthcare Awards no later than August 27, 2010. In an effort to provide an innovative and eco-friendly entry process, once again the CLIO Healthcare Awards will receive submissions online only at www.CLIOHealthcare.com. Professionals now have additional time to refine their entries, including international work, made eligible for the first time.

12 Aug 2010

ALLOZYNE signs worldwide, co-exclusive licensing agreement with Sigma-Aldrich

ALLOZYNE Inc. announced today the signing of a worldwide, co-exclusive licensing agreement with Sigma-Aldrich giving ALLOZYNE a license for the use of cycloaddition chemistry in the development of therapeutics and diagnostics. Sigma-Aldrich currently holds broad, worldwide intellectual property for the use of cycloaddition chemistry to conjugate biomolecules.

12 Aug 2010

AdvanDx announces European launch of CE-IVD marked GNR Traffic Light PNA FISH test

AdvanDx today announced the launch of its CE-IVD marked GNR Traffic Light™ PNA FISH® test in Europe. GNR Traffic Light PNA FISH is the first-ever test capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from positive blood cultures in less than 90 minutes.

12 Aug 2010

RadNet completes acquisition of Health Diagnostics' New Jersey subsidiary

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 191 fully-owned and operated outpatient imaging centers, today reported it has completed the previously announced acquisition of the New Jersey operating subsidiary of Health Diagnostics.

12 Aug 2010

Swift Biosciences completes $3 million Series A financing

Swift Biosciences Inc., a Michigan-based life sciences company, today announced the recent completion of a $3 million Series A financing led by the venture firm DFJ Mercury. DFJ Mercury was joined in the Series A by several Michigan-based individual investors who also helped launch the Company with seed funding in January 2010. Daniel Watkins of DFJ Mercury will join the company's Board of Directors.

12 Aug 2010

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.

11 Aug 2010

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, announced today that it received a Notice of Allowance by the Japanese Patent Office stating a favourable decision for the patent application 2000-547262 developed at the Max-Planck Institute for Molecular Genetics in Berlin, Germany. This patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology and is already granted in Europe with the publication number EP1073770 B1.

11 Aug 2010

Myriad Genetics fourth-quarter revenues increase 9% to $93.9 million

Myriad Genetics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2010.

11 Aug 2010

Clarient receives patent for Mammostrat breast cancer prognostic test

Clarient, Inc. a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United States Patent and Trademark Office and the European Patent Office have allowed patents covering the technology behind Clarient Insight Dx Mammostrat, a test designed to aid in the classification of the risk of recurrence of breast cancer following surgery and initial treatment.

11 Aug 2010

ACD launches RNAscope Formalin-Fixed, Paraffin-Embedded Assay Kit

Advanced Cell Diagnostics, Inc., announces the launch and immediate availability of RNAscope™ FFPE Assay Kit, a line of RUO products designed to detect RNA biomarkers in routine Formalin-Fixed, Paraffin-Embedded tissue specimens with single molecule sensitivity.

From Advanced Cell Diagnostics 11 Aug 2010

UHC awards 3-year single-source agreement for support services to Sodexo

The University HealthSystem Consortium today announced that it has awarded a 3-year single-source agreement for support services to Sodexo, Inc., based in Gaithersburg, Md. The contract became effective on August 1, 2010, and includes two 1-year renewal periods.

10 Aug 2010

GenMark second-quarter revenues increase 162% to $651,000

GenMark Diagnostics, Inc. today reported revenues of $651,000 for the quarter ending June 30, 2010, a 162% increase over second quarter 2009. Net loss for the second quarter was $5.1 million, or $0.60 per share, compared to a net loss of $4.3 million and $1.08 per share for the same period last year.

10 Aug 2010

Epitomics launches EP Clone Rabbit Monoclonal Antibodies

Epitomics, Inc., the rabbit monoclonal antibody company, announces today the launch of EP Clone™ Rabbit Monoclonal Antibodies and their detection systems for pathology applications. These diagnostic immunohistochemistry (IHC) products are manufactured by the In Vitro Diagnostic (IVD) Division of the Company. This new line of products are developed in compliance with regulation for IHC antibodies and detection systems in the United States, these products are manufactured under FDA's Quality System Regulation (21 CFR, Part 820).

9 Aug 2010

Myconostica announces CE marking for MycAssay Aspergillus and Pneumocystis on additional platforms

Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the CE marking of its lead products MycAssay™ Aspergillus and MycAssay™ Pneumocystis on the Roche Lightcycler® 2.0 and Stratagene Mx3000 series platforms.

9 Aug 2010

SQI Diagnostics to raise CDN $5 million through non-brokered private placement

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that it intends to raise gross proceeds of up to CDN $5 million through a non-brokered private placement of up to 2,000,000 units of the Company at a price of $2.50 per unit.

7 Aug 2010

Response Genetics total revenue for second-quarter 2010 increases 197% to $5.6 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and six months ended June 30, 2010.

7 Aug 2010

Diagnostics News and Research

LabCorp announces collaboration between Esoterix Clinical Trials Services, Clearstone Central Laboratories

A*STAR's Singapore Immunology Network, Institut M-rieux and bioM-rieux partner in TB research

Transgenomic second-quarter net loss increases to $1.1 million

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Entry deadline for second annual CLIO Healthcare Awards extended to August 27, 2010

ALLOZYNE signs worldwide, co-exclusive licensing agreement with Sigma-Aldrich

AdvanDx announces European launch of CE-IVD marked GNR Traffic Light PNA FISH test

RadNet completes acquisition of Health Diagnostics' New Jersey subsidiary

Swift Biosciences completes $3 million Series A financing

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Myriad Genetics fourth-quarter revenues increase 9% to $93.9 million

Clarient receives patent for Mammostrat breast cancer prognostic test

ACD launches RNAscope Formalin-Fixed, Paraffin-Embedded Assay Kit

UHC awards 3-year single-source agreement for support services to Sodexo

GenMark second-quarter revenues increase 162% to $651,000

Epitomics launches EP Clone Rabbit Monoclonal Antibodies

Myconostica announces CE marking for MycAssay Aspergillus and Pneumocystis on additional platforms

SQI Diagnostics to raise CDN $5 million through non-brokered private placement

Response Genetics total revenue for second-quarter 2010 increases 197% to $5.6 million

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News